[go: up one dir, main page]

ME01217B - Inhibitori replikacije virusa ljudske imunodeficijencije - Google Patents

Inhibitori replikacije virusa ljudske imunodeficijencije

Info

Publication number
ME01217B
ME01217B MEP-2010-192A MEP19210A ME01217B ME 01217 B ME01217 B ME 01217B ME P19210 A MEP19210 A ME P19210A ME 01217 B ME01217 B ME 01217B
Authority
ME
Montenegro
Prior art keywords
alkyl
bond
optionally substituted
cycloalkyl
het
Prior art date
Application number
MEP-2010-192A
Other languages
English (en)
French (fr)
Inventor
Youla S Tsantrizos
Michael Boes
Christian Brochu
Craig Fenwick
Eric Malenfant
Stephen Mason
Marc Pesant
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38693497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01217(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ME01217B publication Critical patent/ME01217B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1.Antropizomer, racemat, enantiomer, diastereomer ili tautomer jedinjenja predstavljeno formulom (I): u kojoj veza a je dvostruka veza, a veza b je jednostruka veza ili veza a je jednostruka veza, a veza b je dvostruka veza; X je O ili NR1 kada je veza a jednostruka veza; ili X je N kada je veza a dvostruka veza; R1 je H, (C1-6)alkil, (C1-6)haloalkil, (C3-7)cikloalkil-(C1-6)alkil-, aril-(C1-6)alkil- ili Het-(C1-6) alkil-; gde svaki od (C1-6)alkil, (C3-7)cikloalkil-(C1-6)alkil-, aril-(C1-6)alkil- i Het-(C1-6)alkil- je opciono supstituisan sa -OH, -O(C1-6)alkil, -SH, -S(C1-6)alkil, -NH2, -NH(C1-6)alkil ili -N((C1-6)alkil)2; R2 je H, (C1-6)alkil ili -O(C1-6)alkil kada je veza b jednostruka veza; ili R2 je O kada je veza b dvostruka veza; R3 je (C1-6)alkil, (C1-6)haloalkil, (C2-6)alkenil, (C2-6)alkinil, (C3-7)cikloalkil-(C1-6)alkil-, aril-(C1-6)alkil-, Het-(C1-6)alkil- ili -Y- R31, a veza c je jednostruka veza; ili R3 je (C1-6)alkiliden, a veza c je dvostruka veza; gde Y je O ili S, a R31 je (C1-6)alkil, (C1-6)haloalkil, (C2-6)alkenil, (C2-6)alkinil, (C3-7) cikloalkil, aril, (C3-7)cikloalkil-(C1-6)alkil-, aril-(C1-6)alkil- ili Het-(C1-6)alkil-; gde svaki od (C1-6)alkiliden, (C1-6)alkil, (C1-6)haloalkil, (C2-6)alkenil, (C2-6)alkinil, (C3-7) cikloalkil-(C1-6)alkil-, aril-(C1-6)alkil-, Het-(C1-6)alkil- i -Y-R31 je opciono supstituisan sa 1 do 3 supstituenta, svaki nezavisno odabran od (C1-6)alkil, halo, cijano, okso i -O(C1-6)alkil; R4 je aril ili Het, gde svaka aril i Het je opciono supstituisan sa 1 do 5 susptituenata, svaki nezavisno odabran od halo, (C1-6)alkil, (C2-6)alkenil, (C1-6)haloalkil, (C3-7) cikloalki, -OH, -O(C1-6)alkil-, -SH, -S(C1-6)alkil, -NH2, -NH(C1-6)alkil i -N((C1-6)alkil)2; gde je (C1-6)alkil opciono supstituisan sa hidroksi, cijano ili okso; R6 i R7 su svaki nezavisno odabrani od H, halo, (C1-6)alkil i (C1-6)haloalkil; pod uslovom da kada veza a je jednostruka veza i veza b je dvostruka veza; i X je NR1; R1 je H; i R2 je O; i R4 je ne supstituisani fenil; R6 je Cl; R7 je H; i veza c je dvostruka veza; onda R3 nije =CH-CH(CH3)2; i gde Het je 4- do 7-člani zasićeni, nezasićeni ili aromatični heterocikl koji ima 1 do 4 heteroatoma, svaki nezavisno odabran od O, N i S, ili 7- do 14-člani zasićeni, nezasićeni ili aromatični heteropolicikl koji gde god je moguće ima 1 do 5 heteroatoma, svaki nezavisno odabran od O, N i S; ili njegova so ili estar.
2.Jedinjenje prema zahtevu 1, gde R4 je naftil ili fenil, gde je fenil opciono supstituisan sa 1 do 3 supstituenta, svaki odabran od halo, (C1-4)alkil, (C2-4)alkenil, (C1-4)haloalkil, (C3-7) cikloalkil, -OH, -O(C1-4)alkil, -SH, -S(C1-4)alkil, -NH2, -NH(C1-4)alkil i -N((C1-4)alkil)2; gde je (C1-4)alkil opciono supstituisan sa hidroksi, cijano ili okso.
3.Jedinjenje prema zahtevu 1, gde R4 je Het opciono supstituisan sa 1 do 5 supstituenata, svaki nezavisno odabran od halo, (C1-6)alkil, (C2-6)alkenil, (C1-6)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-6)alkil, -SH, -S(C1-6)alkil, -NH2, -NH(C1-6)alkil i -N((C1-6)alkil)2; gde je (C1-6)alkil opciono supstituisan sa hidroksi, cijano ili okso.
4.Jedinjenje prema zahtevu 1, formule (Ia): u kojoj X je O ili NR1; R1 je H, (C1-6)alkil, (C3-7)cikloalkil-(C1-6)alkil-, ili Het-(C1-6)alkil-; gde Het je 4- do 7-člani heterocikl koji ima 1 do 3 heteroatoma, svaki nezavisno odabran od N, O i S; i gde svaki od (C1-6)alkil, (C3-7)cikloalkil-(C1-6)alkil-, i Het-(C1-6)alkil- je opciono supstituisan sa -OH, -O(C1-3)alkil, -NH2, -NH(C1-3)alkil ili -N((C1-3)alkil)2; R2 je O; R3 je (C1-6)alkil ili (C2-6)alkenil; a veza c je jednostruka veza; R4 je naftil ili fenil, gde je fenil opciono supstituisan sa 1 do 3 supstituenta, svaki nezavisno odabran od halo, (C1-4)alkil, (C2-4)alkenil, (C1-4)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-4)alkil, -SH, -S(C1-4)alkil, -NH2, -NH(C1-4)alkil i -N((C1-4)alkil)2; gde je (C1-4) alkil opciono supstituisan sa hidroksi, cijano ili okso; R6 je H, halo, (C1-3)alkil ili (C1-3)haloalkil; R7 je H ili F; ili njegova so ili estar.
5.Jedinjenje prema zahtevu 4, gde R4 je fenil opciono supstituisan sa 1 do 3 supstituenta svaki nezavisno odabran od halo, (C1-4)alkil, (C2-4)alkenil, (C1-4)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-4)alkil, -SH, -S(C1-4)alkil, -NH2, -NH(C1-4)alkil i -N((C1-4)alkil)2; gde je (C1-4)alkil opciono supstituisan sa hidroksi, cijano ili okso.
6.Jedinjenje prema jednom ili više zahteva 1 do 5, gde R6 je H, Cl ili Br, a R7 je H.
7.Jedinjenje prema zahtevu 1, formule (Id): u kojoj R2 is (C1-6)alkil ili -O(C1-6)alkil; R3 je (C1-6)alkil, (C2-6)alkenil, -O-(C1-6)alkil, -O-(C1-6)haloalkil, -O-(C2-6)alkenil, -O-(C2-6) alkinil, -O-(C3-7)cikloalkil, -O-aril, (C3-7)cikloalkil-(C1-6)alkil-O-, aril-(C1-6)alkil-O- ili Het-(C1-6)alkil-O-; gde svaki od -O-(C1-6)alkil, -O-(C2-6)alkenil, -O-(C2-6)alkinil, -O-(C3-7)cikloalkil, -O-aril, (C3-7)cikloalkil-(C1-6)alkil-O-, aril-(C1-6)alkil-O- i Het-(C1-6)alkil-O- je opciono supstituisan sa 1 do 3 supstituenta svaki nezavisno odabran od (C1-6)alkil, halo, cijano, okso i -O(C1-6)alkil; a veza c je jednostruka veza; ili R3 je (C1-6)alkiliden, a veza c je dvostruka veza; R4 je naftil ili fenil, gde je fenil opciono supstituisan sa 1 do 3 supstituenta svaki nezavisno odabran od halo, (C1-4)alkil, (C2-4)alkenil, (C1-4)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-4)alkil, -SH, -S(C1-4)alkil, -NH2, -NH(C1-4)alkil i -N((C1-4)alkil)2; gde je (C1-4) alkil opciono supstituisan sa hidroksi, cijano ili okso; ili R4 je Het opciono supstituisan sa 1 do 5 supstituenata svaki nezavisno odabran od halo, (C1-6)alkil, (C2-6)alkenil, (C1-6)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-6)alkil, -SH, -S(C1-6)alkil, -NH2, -NH(C1-6)alkil i -N((C1-6)alkil)2; gde je (C1-6)alkil opciono supstituisan sa hidroksi, cijano ili okso; R6 je H, halo, (C1-3)alkil ili (C1-3)haloalkil; i R7 je H ili F; ili njegova so ili estar.
8.Jedinjenje prema zahtevu 7, gde R4 je fenil opciono supstituisan sa 1 do 3 supstituenta, svaki nezavisno odabran od halo, (C1-4)alkil, (C2-4)alkenil, (C1-4)haloalkil, (C3-7)cikloalkil, -OH, -O(C1-4)alkil, -SH, -S(C1-4)alkil, -NH2, -NH(C1-4)alkil i -N((C1-4)alkil)2; gde je (C1-4)alkil opciono supstituisan sa hidroksi, cijano ili okso.
9.Jedinjenje prema zahtevu 7, gde R4 je Het opciono supstituisan sa 1 do 3 supstituenta svaki nezavisno odabran od halo, (C1-6)alkil i -O(C1-6)alkil; gde Het je 5- ili 6-člani heterocikl koji ima 1 do 3 heteroatoma, svaki nezavisno odabran od N, O i S; ili Het je 9- ili 10-člani heteropolicikl koji ima 1 do 3 heteroatoma, svaki nezavisno odabran od N, O i S.
10.Jedinjenje prema zahtevu 1, formule u kojoj R2, R3, R4, R6 i R7 su definisani prema sledećoj tabeli: Jed. R2 R3 R4 R6 R7 1001 CH3 Br H 1002 CH3 Br H 1003 CH3 Br H 1004 CH3 Br H 1005 CH3 Cl H 1006 CH3 Br H 1007 CH3 Br H 1008 CH3 Cl H Jed. R2 R3 R4 R6 R7 1009 -OCH3 Br H 1010 -CH(CH3)2 Br H 1011 CH3 H H 1012 CH3 Cl H 1013 CH3 Cl H 1014 CH3 Cl H 1015 CH3 Cl H 1016 CH3 Cl H Jed. R2 R3 R4 R6 R7 1017 CH3 Cl H 1018 CH3 Cl H 1019 CH3 Cl H 1020 CH3 Br H 1021 CH3 Cl H 1022 CH3 Br H 1023 CH3 Br H Jed. R2 R3 R4 R6 R7 1024 CH3 Cl H 1025 CH3 Br H 1026 CH3 Br H 1027 CH3 Br H 1028 CH3 Br H 1029 CH3 Cl H 1030 CH3 Cl H 1031 CH3 Cl H Jed. R2 R3 R4 R6 R7 1032 CH3 Br H 1033 CH3 H H 1034 CH3 Cl H 1035 CH3 Br H 1036 CH3 Cl H 1037 CH3 Cl H 1038 CH3 Br H 1039 CH3 Br H Jed. R2 R3 R4 R6 R7 1040 CH3 Br H 1041 CH3 Br H 1042 CH3 Br H 1043 CH3 Br H 1044 CH3 Br H 1045 CH3 Br H 1046 CH3 Br H Jed. R2 R3 R4 R6 R7 1047 CH3 Br H 1048 CH3 Br H 1049 CH3 Br H 1050 CH3 Br H 1051 CH3 Br H 1052 CH3 Br H 1053 CH3 F F 1054 CH3 Cl H Jed. R2 R3 R4 R6 R7 1055 CH3 Br H 1056 CH3 Cl H 1057 CH3 Cl H 1058 CH3 Cl H 1059 CH3 Cl H 1060 CH3 Cl H 1061 CH3 Cl H 1062 CH3 Cl H Jed. R2 R3 R4 R6 R7 1063 CH3 Cl H 1064 CH3 Cl H 1065 CH3 Cl H 1066 CH3 Cl H 1067 CH3 Cl H 1068 CH3 Cl H 1069 CH3 Cl H 1070 CH3 Cl H Jed. R2 R3 R4 R6 R7 1071 CH3 Cl H 1072 CH3 Cl H 1073 CH3 Cl H 1074 CH3 Cl H 1075 CH3 Cl H 1076 CH3 Cl H 1077 CH3 Cl H 1078 CH3 Cl H Jed. R2 R3 R4 R6 R7 1079 CH3 Br H 1080 CH3 Cl H 1081 CH3 Cl H 1082 CH3 H H 1083 CH3 Cl H 1084 CH3 Cl H 1085 CH3 Cl H 1086 CH3 Cl H Jed. R2 R3 R4 R6 R7 1087 CH3 Cl H 1088 CH3 Cl H 1089 CH3 Cl H 1090 CH3 Cl H 1091 CH3 Cl H 1092 CH3 Cl H 1093 CH3 Cl H 1094 CH3 Cl H Jed. R2 R3 R4 R6 R7 1095 CH3 Cl H 1096 CH3 Cl H 1097 CH3 Cl H 1098 CH3 Cl H 1099 CH3 Cl H 1100 CH3 Cl H 1101 -CH2CH3 Cl H 1102 CH3 Cl H Jed. R2 R3 R4 R6 R7 1103 CH3 Cl H 1104 CH3 Cl H 1105 CH3 Cl H 1106 CH3 Br H 1107 CH3 Cl H 1108 CH3 Cl H 1109 CH3 Cl H 1110 CH3 Cl H Jed. R2 R3 R4 R6 R7 1111 CH3 Cl H 1112 CH3 Cl H 1113 CH3 Cl H 1114 CH3 Cl H 1115 CH3 Cl H 1116 CH3 Cl H 1117 CH3 Cl H 1118 CH3 Cl H 1119 CH3 Cl H Jed. R2 R3 R4 R6 R7 1120 CH3 Cl H 1121 CH3 Cl H 1122 CH3 Cl H 1123 CH3 Cl H 1124 CH3 Cl H 1125 CH3 Cl H 1126 CH3 Cl H 1127 CH3 Cl H Jed. R2 R3 R4 R6 R7 1128 CH3 Cl H 1129 CH3 Cl H 1130 CH3 Cl H 1131 CH3 Cl H 1132 CH3 Cl H 1133 CH3 Cl H 1134 CH3 Cl H 1135 CH3 Cl H Jed. R2 R3 R4 R6 R7 1136 CH3 Cl H 1137 CH3 Cl H 1138 CH3 Cl H 1139 CH3 Cl H 1140 CH3 Cl H 1141 CH3 Cl H 1142 CH3 Cl H 1143 CH3 Cl H Jed. R2 R3 R4 R6 R7 1144 CH3 Cl H 1145 CH3 Cl H 1146 CH3 Cl H 1147 CH3 Cl H 1148 CH3 Cl H 1149 CH3 Cl H 1150 CH3 Cl H 1151 CH3 Cl H Jed. R2 R3 R4 R6 R7 1152 CH3 H H 1153 CH3 Cl H 1154 CH3 Cl H 1155 CH3 Cl H 1156 CH3 Cl H 1157 CH3 H H 1158 CH3 H H 1159 CH3 H H Jed. R2 R3 R4 R6 R7 1160 CH3 H H 1161 CH3 H H 1162 CH3 Cl H 1163 CH3 H H 1164 CH3 Br H 1165 CH3 Cl H 1166 CH3 Cl H
11.Jedinjenje prema zahtevu 1, formule u kojoj R1, R3, R4 i R6 su definisani prema sledećoj tabeli: Jed. R1 R3 R4 R6 2001 H Cl 2002 Cl 2003 Cl 2004 H Br 2005 H H 2006 H Br Jed. R1 R3 R4 R6 2007 Cl 2008 Cl 2009 CH3 Cl 2010 Cl 2011 Cl
12.Jedinjenje prema zahtevu 1, formule u kojoj R3, R4 i R6 su definisani prema sledećoj tabeli: Jed R3 R4 R6 3001 Br 3002 Br 3003 Br 3004 Br
13.Farmaceutska kompozicija koja sadrži terapeutsku efikasnu količinu jedinjenja formule (I) prema zahtevu 1, ili njegovu farmaceutski prihvatljivu so ili estar, i jedan ili više farmaceutski prihvatljivih nosača.
14.Farmaceutska kompozicija prema zahtevu 13, dodatno sadrži bar jedan drugi antivirusni agens.
15. Primena jedinjenja formule (I) prema zahtevu 1, ili njegove farmaceutski prihvatljive soli ili estra, za proizvodnju medikamenta za lečenje HIV infekcije kod sisara koji imaju ili kod kojih postoji rizik od infekcije.
MEP-2010-192A 2006-05-16 2007-05-14 Inhibitori replikacije virusa ljudske imunodeficijencije ME01217B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74731106P 2006-05-16 2006-05-16
EP07784947A EP2019825B9 (en) 2006-05-16 2007-05-14 Inhibitors of human immunodeficiency virus replication
PCT/CA2007/000845 WO2007131350A1 (en) 2006-05-16 2007-05-14 Inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
ME01217B true ME01217B (me) 2013-03-20

Family

ID=38693497

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2010-192A ME01217B (me) 2006-05-16 2007-05-14 Inhibitori replikacije virusa ljudske imunodeficijencije

Country Status (33)

Country Link
US (1) US7939545B2 (me)
EP (1) EP2019825B9 (me)
JP (3) JP5144649B2 (me)
KR (1) KR20090007755A (me)
CN (1) CN101448812B (me)
AR (1) AR060949A1 (me)
AT (1) ATE479673T1 (me)
AU (1) AU2007250427B2 (me)
BR (1) BRPI0711642A2 (me)
CA (1) CA2650798C (me)
CL (1) CL2007001392A1 (me)
DE (1) DE602007008874D1 (me)
DK (1) DK2019825T3 (me)
EA (1) EA018655B1 (me)
EC (1) ECSP088784A (me)
ES (1) ES2352576T3 (me)
HR (1) HRP20100553T1 (me)
IL (1) IL195244A0 (me)
ME (1) ME01217B (me)
MX (1) MX2008014459A (me)
MY (1) MY148534A (me)
NO (1) NO20084081L (me)
NZ (1) NZ573526A (me)
PE (1) PE20080093A1 (me)
PL (1) PL2019825T3 (me)
PT (1) PT2019825E (me)
RS (1) RS51465B (me)
SI (1) SI2019825T1 (me)
TW (1) TWI406856B (me)
UA (1) UA100005C2 (me)
UY (1) UY30350A1 (me)
WO (1) WO2007131350A1 (me)
ZA (1) ZA200808022B (me)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2009062308A1 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
KR20100097156A (ko) * 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011133707A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
SG186820A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
BR112012033689A2 (pt) * 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
TW201302761A (zh) 2011-04-04 2013-01-16 Gilead Sciences Inc Ｈｉｖ抑制劑之固態形式
AU2012240314A1 (en) * 2011-04-04 2013-05-02 Gilead Sciences, Inc. Process for the preparation of an HIV integrase inhibitor
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
WO2013002357A1 (ja) * 2011-06-30 2013-01-03 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6099149B2 (ja) 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
EP2781519B1 (en) * 2011-11-15 2019-10-30 ST Pharm Co., Ltd. Novel antiviral pyrrolopyridine derivative and a production method for same
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
MX2014005002A (es) 2012-04-20 2014-07-09 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih.
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140094609A1 (en) * 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970273B1 (en) 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105189510B (zh) 2013-03-13 2017-05-17 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
WO2014159076A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2970274B1 (en) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
ES2654242T3 (es) 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt) 2014-02-19 2018-09-28 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ES2670010T3 (es) 2014-02-20 2018-05-29 VIIV Healthcare UK (No.5) Limited Macrociclos de ácido piridin-3-il acético como inhibidores de replicación del virus de inmunodeficiencia humana
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
UY36217A (es) 2014-07-21 2016-02-29 Viiv Healthcare Uk Ltd Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MA43120A (fr) 2015-05-29 2018-09-05 Shionogi & Co Dérivé tricyclique contenant de l'azote présentant une activité inhibitrice de la réplication du vih
AU2016290152A1 (en) 2015-07-06 2018-01-18 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CN107835808A (zh) 2015-07-08 2018-03-23 Viiv保健英国第五有限公司 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
WO2017006281A1 (en) 2015-07-09 2017-01-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA2991464A1 (en) 2015-07-09 2017-01-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
BR112018002403A2 (pt) 2015-08-07 2018-09-18 Viiv Healthcare Uk No 5 Ltd composto, e, composição útil e método para tratar infecção de hiv
JP2018522924A (ja) 2015-08-10 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのイミダゾピリジン大環状化合物
AR105653A1 (es) * 2015-08-11 2017-10-25 VIIV HEALTHCARE UK (Nº 5) LTD Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CA2995042A1 (en) 2015-08-12 2017-02-16 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10214516B2 (en) * 2015-08-12 2019-02-26 VIIV Healthcare UK (No.5) Limited 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CN108368093A (zh) * 2015-08-20 2018-08-03 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物
US20200325127A1 (en) 2016-05-11 2020-10-15 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195113A1 (en) 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20190152957A1 (en) 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565810A1 (en) 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2020503348A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463518A (en) * 1987-09-02 1989-03-09 Otsuka Pharma Co Ltd Antiarrhythmic agent
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
FR2772761B1 (fr) 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
CZ20011965A3 (cs) * 1998-12-04 2001-09-12 Bristol-Myers Squibb Company Derivát v poloze 3 substituovaného 4-arylchinolin-2-onu jako modulátor draslíkového kanálku
EP1255741A2 (en) 2000-02-01 2002-11-13 Cor Therapeutics, Inc. 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
RS51465B (sr) 2011-04-30
UY30350A1 (es) 2008-01-02
DK2019825T3 (da) 2010-11-22
PE20080093A1 (es) 2008-03-25
CN101448812B (zh) 2012-07-04
EA200802209A1 (ru) 2009-06-30
ECSP088784A (es) 2008-10-31
JP2014139242A (ja) 2014-07-31
NO20084081L (no) 2008-12-12
TWI406856B (zh) 2013-09-01
CN101448812A (zh) 2009-06-03
EP2019825B1 (en) 2010-09-01
SI2019825T1 (sl) 2011-01-31
JP5144649B2 (ja) 2013-02-13
BRPI0711642A2 (pt) 2011-11-29
ZA200808022B (en) 2009-09-30
ES2352576T3 (es) 2011-02-21
MX2008014459A (es) 2008-11-26
UA100005C2 (ru) 2012-11-12
CL2007001392A1 (es) 2008-01-18
MY148534A (en) 2013-04-30
EP2019825B9 (en) 2011-01-26
WO2007131350A1 (en) 2007-11-22
ATE479673T1 (de) 2010-09-15
CA2650798A1 (en) 2007-11-22
PT2019825E (pt) 2010-11-08
US20080221159A1 (en) 2008-09-11
PL2019825T3 (pl) 2011-02-28
AU2007250427B2 (en) 2012-08-30
EA018655B1 (ru) 2013-09-30
IL195244A0 (en) 2009-09-22
AR060949A1 (es) 2008-07-23
AU2007250427A1 (en) 2007-11-22
EP2019825A1 (en) 2009-02-04
DE602007008874D1 (de) 2010-10-14
HK1131153A1 (en) 2010-01-15
ES2352576T8 (es) 2011-11-22
HRP20100553T1 (hr) 2010-11-30
NZ573526A (en) 2012-03-30
JP5530506B2 (ja) 2014-06-25
JP2009537459A (ja) 2009-10-29
CA2650798C (en) 2014-01-14
JP2013060454A (ja) 2013-04-04
KR20090007755A (ko) 2009-01-20
EP2019825A4 (en) 2009-06-03
US7939545B2 (en) 2011-05-10
TW200812997A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
ME01217B (me) Inhibitori replikacije virusa ljudske imunodeficijencije
RU2503679C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
MX2009003410A (es) Fosfoindoles enantiomericamente puros como inhibidores de vih.
HRP20120328T2 (hr) Inhibitori replikacije virusa humane imunodeficijencije
JP2015500843A5 (me)
JP2015509535A5 (me)
JP2014511892A5 (me)
JP2011503118A5 (me)
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
AR049540A1 (es) Derivados de quinazolindiona como inhibidores del parp; metodos para su preparacion; composiciones farmaceuticas que los contienen como ingrediente activo y su uso en medicamentos para el tratamiento o prevencion del cancer.
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
AR080870A1 (es) Propanoato cristalino de (s)-isopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino, composiciones farmaceuticas que los contienen y uso del mismo en el tratamiento de infecciones virales, en particul
NZ588830A (en) Inhibitors of protein kinases
AR078121A1 (es) Compuestos de sales de amonio cuaternario y composiciones farmaceuticas
JP2013542261A5 (me)
JP2017518334A5 (me)
JP2005519916A5 (me)
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
JP2015025011A5 (me)
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
JP2010511635A5 (me)
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
JP2019510794A5 (me)